Skip to main content
. Author manuscript; available in PMC: 2024 Mar 8.
Published in final edited form as: Ann Surg Oncol. 2023 Nov 15;31(3):1898–1905. doi: 10.1245/s10434-023-14564-3

Table 1:

Univariate analysis of patient and lesion factors and preoperative CT imaging measurements as risk factors for CR-POPF.

Univariate Analysis
CR-POPF (%) p value
Sex
  Female 14/102 (13.7%) 0.342
  Male 19/102 (18.6%)

Race
  White 21/149 (14.1%) 0.367
  Black 7/35 (20.0%)
  Other 5/20 (25.0%)

Age (years)
  ≥ 70 11/75 (14.7%) 0.655
  < 70 22/129 (17.1%)

BMI (kg/m2)
  ≥ 30 11/46 (23.9%) 0.105
  < 30 22/158 (13.9%)

Pre-operative Diagnosis
  Malignant 23/162 (14.2%) 0.132
  Non-malignant 10/42 (23.8%)

Neoadjuvant Chemotherapy
  No 21/107 (19.6%) 0.160
  Yes 12/97 (12.4%)

Neoadjuvant Radiotherapy
  No 29/189 (15.4%) 0.272
  Yes 4/15 (26.7%)

Gland Texture
  Soft 21/66 (31.8%) <0.001
  Intermediate 7/71 (9.9%)
  Firm 5/67 (7.5%)

Duct Size (mm)
  > 3.0 4/82 (4.9%) <0.001
  ≤ 3.0 29/122 (23.8%)

Abdominal wall
  > 1.95cm 20/102 (19.6%) 0.183
  ≤ 1.95cm 13/102 (12.7%)

PTP
  > 5.8cm 24/101 (23.8%) 0.004
  ≤ 5.8cm 9/103 (8.7%)

Pancreatic Neck
  > 1.3cm 22/100 (22.0%) 0.027
  ≤ 1.3cm 11/104 (10.6%)

BMI = Body mass index, PTP = pancreas to peritoneum.